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Abstract: A study of factors proposed to affect metallothionein-3 (MT3) function was carried out
to elucidate the opaque role MT3 plays in human metalloneurochemistry. Gene expression of Mt2
and Mt3 was examined in tissues extracted from the dentate gyrus of mouse brains and in human
neuronal cell cultures. The whole-genome gene expression analysis identified significant variations
in the mRNA levels of genes associated with zinc homeostasis, including Mt2 and Mt3. Mt3 was
found to be the most differentially expressed gene in the identified groups, pointing to the existence
of a factor, not yet identified, that differentially controls Mt3 expression. To examine the expression of
the human metallothioneins in neurons, mRNA levels of MT3 and MT2 were compared in BE(2)C
and SH-SY5Y cell cultures treated with lead, zinc, cobalt, and lithium. MT2 was highly upregulated
by Zn2+ in both cell cultures, while MT3 was not affected, and no other metal had an effect on either
MT2 or MT3.
Keywords: metallothionein; MT3; metalloneurochemistry; lead neurotoxicity; gene expression;
microarrays; dentate gyrus
1. Introduction
Mammalian metallothionein-3 isoform (MT3) is an unusual protein with a puzzling role in
neurochemistry [1]. It has the hallmarks of a typical mammalian metallothionein and is comprised
of 68 amino acids, 20 of which are cysteines. Hence, it is assumed that, like other metallothioneins
(MT), it binds essential metal ions such as zinc (Zn) and copper (Cu) and sequesters toxic metal ions
such as cadmium (Cd) and silver (Ag) [2]. Most mammalian metallothioneins are induced by high
levels of zinc by a mechanism initiated by Zn2+ binding to a metal-responsive transcription factor [3].
Because toxic metals such as Cd2+ and Ag+ displace zinc bound to metallothionein, their presence also
indirectly leads to elevated MT levels.
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Despite the presence of the canonical 20 cysteines in its structure, MT3 was first identified not as a
metallothionein, but as an inhibitor of neuronal growth [4,5]. Although the molecular basis of its ability
to inhibit neuronal growth is not understood, the effect has been connected to the seven-amino-acid
acidic region that is unique to MT3 [6]. Recently, MT3 has been shown to bind to β-actin and facilitate
actin polymerization [7]. β-Actin polymerization is involved in cytoskeletal growth, fueling speculation
that the neuronal growth inhibitor effects of MT3 could occur via an interaction with β-actin [8].
MT3 is specifically expressed in the normal human brain and is significantly under-expressed in
the brains of patients with Alzheimer’s disease [1,4,9]. Little is known about what constitutes “normal”
bioinorganic chemistry in the central nervous system [10], though recent works point to essential roles
for zinc and copper ions in the brain and suggest that both ions can function in neuronal signaling [11].
Therefore, it is noteworthy that MT3 might modulate the bioinorganic chemistry of essential (zinc,
copper), therapeutic (lithium) and toxic (lead) metal ions in the brain. MT3 has been speculated to
play a special role in mediating the chemistry of copper, which has been found in the brain not only as
bound to biomolecules and highly regulated, but also as existing in dynamic, loosely bound pools [11].
We have speculated that MT3 might be involved in the effect that the exposure to lead (Pb) has on
brain development [12]. It is well known that exposure to lead during childhood leads to irreversible
long-lasting developmental effects, including perhaps an increased risk of certain forms of mental
illnesses [13,14]. Based on a report that lithium chloride treatment leads to decreased levels of Mt3 in
mice brains, we have considered the possibility that MT3 might be involved in the pharmacological
benefits of lithium treatment for people suffering from bipolar mood disorder [15].
In this paper, we explore factors that may potentially impact MT3 gene expression and, indirectly,
function. MT3 is known to be abundant in the dentate gyrus (DG) [16]. Our study of gene expression
in the DG of a population of litter-mate matched mice, presented here, revealed significant differences
between tested mice in the expression levels of Mt3, along with a suite of other genes associated
with zinc homeostasis. Significantly, Mt2 was upregulated in one population of mice, while Mt3 was
upregulated in the other population of mice, pointing to a very different mechanism of regulation of
these two metallothioneins.
We also examine some inorganic factors that may have an impact on expression levels of
metallothioneins in human neuronal cells. There is conflicting published data about the role that metal
ions have on the MT3 levels, pointing to the importance of studying MT3 expression in multiple cell
lines [17–19]. We show that, compared to MT2, MT3 responds differently to identical metal treatments.
The effects that metal ions have on MT3 levels are far more modest than the effects that these metal ions
have on MT2 levels. This fact, again, is pointing to a possible regulatory mechanism that differentially
controls the expression of MT2 vs. MT3 in neuronal tissues.
2. Results
This study focused on gaining a better understanding of MT3 metalloneurochemistry by
examining relationships between Mt3/Mt2 and known zinc homeostasis gene expression in mice
brains and by comparing how MT3 and MT2 levels in neuronal cell cultures respond to metal ion
treatments. Ultimately, this work is part of ongoing efforts in our laboratories to connect molecular-level
knowledge about the metal-mediated processes in which MT3 participates and its more systemic role
in mammal neurobiology.
2.1. Analysis of Expression of Zinc Homeostasis Genes in Mice Dentate Gyrus
The expression profiles of genes related to Zn homeostasis were assessed using data mining in
a whole-genome gene expression dataset that was produced using DG tissues extracted from adult
mice brain samples. The dataset was generated by microarray analysis of the mouse gene complement
represented by 60,000 probes on Agilent gene expression arrays and consisted of 21,000 genes that
were identified as present based on their hybridization signals above the background.
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Gene Ontology search for cellular zinc ion homeostasis and related terms revealed 39 genes,
25 of which were found to be expressed in DG based on our microarray dataset (Table 1). Among
these genes, there were three that code for metallothionein proteins related to Zn-ion transport and
all the major zinc transporters from the Solute Carrier Protein families 30 and 39. Using hierarchical
clustering, a search for possible patterns in expression of these genes in the DG tissue samples revealed
a presence of two groups of animals. Nearly equal in size, these two groups can be identified by their
group-specific co-expression patterns of Zn-binding transporters (Figure 1).
Table 1. Genes related to Zn ion homeostasis. Out of the 39 genes listed in Gene Ontology (GO) as
associated with Zn ion homeostasis, 25 were expressed above background levels in the hippocampal
dentate gyrus samples in this study (shown in red).
Gene Gene/Product Name GO Term Term Description Registry
Ap3b1 adaptor-related protein complex3, beta 1 subunit GO:0006829
calcium channel
regulator activity MGI:MGI:4441257|PMID:17349999





Atp13a2 ATPase type 13A2 GO:0006882 cellular zinc ionhomeostasis MGI:MGI:4834177|GO_REF:0000096
Gtf2i general transcription factor II I GO:0051481 cellular zinc ionhomeostasis MGI:MGI:4417868|GO_REF:0000096
Mt1 Metallothionein-1 GO:0006882 cellular zinc ionhomeostasis MGI:MGI:2177111|PMID:11792622
Mt2 Metallothionein-2 GO:0006882 cellular zinc ionhomeostasis MGI:MGI:2177111|PMID:11792622
Mt3 Metallothionein-3 GO:0006882 cellular zinc ionhomeostasis MGI:MGI:5315330|PMID:21359432
Nrxn2 neurexin II GO:0005246 calcium channelregulator activity MGI:MGI:3040168|PMID:12827191
S100a6
ref|Mus musculus S100 calcium
binding protein A6 (calcyclin)
(S100a6), mRNA [NM_011313]
GO:0005509 calcium ionbinding MGI:MGI:4834177|GO_REF:0000096
S100b
ref|Mus musculus S100 protein,
beta polypeptide, neural
(S100b), mRNA [NM_009115]
GO:0005509 calcium ionbinding MGI:MGI:4417868|GO_REF:0000096
Slc30a1 solute carrier family 30 (zinctransporter), member 1 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:3056220|PMID:15452870
Slc30a3 solute carrier family 30 (zinctransporter), member 3 GO:0032119
cellular zinc ion
homeostasis MGI:MGI:4441264|PMID:16741752





Slc30a5 solute carrier family 30 (zinctransporter), member 5 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:4834177|GO_REF:0000096





Slc30a9 solute carrier family 30 (zinctransporter), member 9 GO:0006829
calcium channel
regulator activity MGI:MGI:1354194|GO_REF:0000004
Slc39a1 solute carrier family 39 (zinctransporter), member 1 GO:0006829
calcium channel
regulator activity MGI:MGI:2683827|PMID:14525987
Slc39a10 solute carrier family 39 (zinctransporter), member 10 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:5586917|PMID:25074913
Slc39a11 solute carrier family 39 (metalion transporter), member 11 GO:0006829
calcium channel
regulator activity MGI:MGI:1354194|GO_REF:0000004
Slc39a12 solute carrier family 39 (zinctransporter), member 12 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:4459044|GO_REF:0000033
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Table 1. Cont.
Gene Gene/Product Name GO Term Term Description Registry
Slc39a13 solute carrier family 39 (metalion transporter), member 13 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:4834177|GO_REF:0000096
Slc39a14 solute carrier family 39 (zinctransporter), member 14 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:4834177|GO_REF:0000096
Slc39a3 solute carrier family 39 (zinctransporter), member 3 GO:0006829
calcium channel
regulator activity MGI:MGI:2683827|PMID:14525987
Slc39a6 solute carrier family 39 (metalion transporter), member 6 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:4834177|GO_REF:0000096
Slc39a7 solute carrier family 39 (zinctransporter), member 7 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:4459044|GO_REF:0000033
Atp7b ATPase, Cu++ transporting,beta polypeptide GO:0006882
cellular zinc ion
homeostasis MGI:MGI:1100407|PMID:9392450
Cp ceruloplasmin GO:0006879 cellular iron ionhomeostasis MGI:MGI:2152098|GO_REF:0000002
Heph hephaestin GO:0006879 cellular iron ionhomeostasis MGI:MGI:2152098|GO_REF:0000002
Kel Kell blood group GO:0006874 cellular calcium ionhomeostasis MGI:MGI:5581641|PMID:23122227
Pik3c2a
phosphatidylinositol 3-kinase,
C2 domain containing, alpha
polypeptide
GO:0071583 zinc II iontransport MGI:MGI:5543317|PMID:23823722










Slc30a7 solute carrier family 30 (zinctransporter), member 7 GO:0032119
cellular zinc ion
homeostasis PMID:17720550
Slc30a8 solute carrier family 30 (zinctransporter), member 8 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:4417868|GO_REF:0000096
Slc39a2 solute carrier family 39 (zinctransporter), member 2 GO:0006829
calcium channel
regulator activity MGI:MGI:2683827|PMID:14525987
Slc39a4 solute carrier family 39 (zinctransporter), member 4 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:3028750|PMID:14612438
Slc39a5 solute carrier family 39 (metalion transporter), member 5 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:3522410|PMID:15358787
Slc39a8 solute carrier family 39 (metalion transporter), member 8 GO:0006882
cellular zinc ion
homeostasis MGI:MGI:4459044|GO_REF:0000033
Slc39a9 solute carrier family 39 (zinctransporter), member 9 GO:0006829
calcium channel
regulator activity MGI:MGI:1354194|GO_REF:0000004
To determine the specific Zn transporters whose expression drives the separation between the
two animal groups, we performed a t-test analysis of gene expression between these groups. The
t-test analysis was followed by false discovery rate (FDR) correction using the Benjamini-Hochberg
procedure. The analysis revealed 11 genes coding for metallothioneins and transporters (shown in
color in Table 2) as having a major impact on the segregation of the animal samples into two groups.
Re-clustering the expression profiles of the samples based on these 11 genes (Figure 2) revealed two
groups, denoted Groups A and B. Group A is characterized by having the genes coding for Mt2
and S100b (Ca-binding protein B) upregulated. The remaining 9 of the 11 discriminating genes were
upregulated in Group B, with Mt3 showing the largest difference in its expression level when compared
to that in Group A.
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Figure 1. Hierarchical clustering of gene expression profiles related to the expression of Zn 
transporters. Genes coding for Zn transporters are shown as rows, and individually tested animal 
samples are shown as columns. The expression changes in the heat map are represented by z-scores 
that are color-coded according to their values: red squares correspond to positive changes in 
expression levels (upregulation); blue squares correspond to negative changes in gene expression 
(downregulation); and white represents the absence of changes. Hierarchical clustering of the gene 
expression profiles revealed the presence of two distinct groups of animals, shown as green and blue 
trees, respectively, on the top of the figure. 
Figure 1. Hierarchical clustering of gene expression profiles related to the expression of Zn transporters.
Genes coding for Zn transporters are shown as rows, and individually tested animal samples are
shown as columns. The expression changes in the heat map are represented by z-scores that are
color-coded according to their values: red squares correspond to positive changes in expression levels
(upregulation); blue squares correspond to negative changes in gene expression (downregulation);
and white represents the absence of changes. Hierarchical clustering of the gene expression profiles
revealed the presence of two distinct groups of animals, shown as green and blue trees, respectively, on
the top of the figure.
Table 2. Zn transporter genes that differentiate the two identified animal groups. Eleven genes, shown
in red and blue, account for the major differences between the two animal groups identified in Figure 1.
Other Zn transporter genes do not show statistically significant changes in expression levels between
the groups. Among the 11 differentially expressed genes, two (Mt2 and S100b, shown in blue) are





Value, Group B log2R
Ap3d1 0.000 Yes 10.234 10.015 0.219
Atp13a2 0.002 Yes 12.355 12.143 0.212
Mt2 0.000 Yes 15.108 15.370 −0.262
Mt3 0.000 Yes 15.251 14.301 0.950
Nrxn2 0.002 Yes 12.817 12.617 0.200
S100a6 0.000 Yes 10.282 9.739 0.542
Slc30a1 0.000 Yes 8.177 7.487 0.690
Slc39a7 0.023 Yes 11.370 11.198 0.171
S100b 0.000 Yes 11.140 11.634 −0.494
Slc30a3 0.000 Yes 9.947 9.349 0.598
Slc39a3 0.000 Yes 10.368 10.054 0.314
Slc30a9 0.162 No 10.367 10.208 0.159
Gtf2i 1.000 No 11.863 11.918 −0.055
Mt1 0.165 No 7.607 7.404 0.203
Mt1 1.000 No 15.846 15.801 0.046
Slc30a4 1.000 No 8.711 8.744 −0.033
Slc30a5 1.000 No 8.351 8.345 0.006
Slc30a6 0.880 No 6.906 6.749 0.157
Slc30a9 0.536 No 7.993 7.851 0.143
Slc39a1 1.000 No 10.034 10.087 −0.053
Slc39a10 0.075 No 9.312 9.489 −0.176
Slc39a11 1.000 No 9.436 9.497 −0.061
Slc39a12 1.000 No 8.267 8.215 0.053
Slc39a13 0.092 No 7.053 7.399 −0.346
Slc39a14 1.000 No 8.260 8.351 −0.092
Slc39a6 1.000 No 10.298 10.241 0.057
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Figure 2. Gen expression profile clustering based on t genes that differentiate animal groups
A and B. Genes are shown as rows, and animals (dentate gyrus samples) are shown as columns. The
expression changes in the heat map are represented by z-scores that are color-coded according to their
values: red squares correspond to positive changes in expression levels (upregulation); blue squares
correspond to negative changes in gene expression (downregulation); and white represents the absence
of changes.
To find other genes and molecular functions that distinguish Group A from Group B, in addition
to those involved in Zn-ion transport, we performed a global (genome-wide) comparison of gene
expression between the two groups and analyzed functional enrichment of the genes that are expressed
differently in Group A vs. Group B. We found that both groups had a large number of over-expressed
genes coding for metal-binding proteins, but those genes that were found to be upregulated in
Group A were different from those upregulated in Group B. In particular, about 250 of such genes
were upregulated in Group A, while 237 different genes were upregulated in Group B (Table S1).
In addition, Group A had a significant enrichment in genes related to synaptic function and signal
transduction pathways.
The gene set that was upregulated in Group B was marked with statistically significant
upregulation. These genes are enriched in functional categories related to ribosomal function,
active transcription and translation, and other processes characteristic of metabolically active cells.
Remarkably, in this group, several large subsets of upregulated genes are disease-related, and include
genes involved in functional pathways associated with Huntington’s, Parkinson’s, and Alzheimer’s
diseases. The common regulatory themes governing these differentially expressed genes in the dentate
gyrus of the two groups of mice still remain to be found. It is also noteworthy that these differences
are not related to differences in sex.
2.2. Analysis of MT2 and MT3 mRNA Expression after Metal Treatment
In order to measure the relative expression of MT2/3 mRNA in cells exposed to various excess
metal treatments, RNA was extracted and reverse transcribed to yield a cDNA library, followed
by qPCR-based determination of relative gene expression levels. While different time points were
explored (data not shown), the 4 h post-exposure results were used for this study. Tables 3 and 4
present the change in MT2 and MT3 expression relative to non-metal treated controls and normalized
to the control gene HSP90ABI. Based on the qPCR data, MT2, in both BE(2)C and SHSY5Y cell lines,
was highly upregulated in the presence of 100 µM Zn2+. The data also show, with equal clarity, that
100 µM Zn2+ had no effect on MT3 levels in either cell line. No other metal had a significant effect on
either MT2 or MT3 levels in these cell lines (data from all experiments shown in Figure S1). Preliminary
studies indicated that Cu(II) did not have a statistically significant effect on MT3 expression.
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Table 3. Relative MT2 mRNA levels after metal treatment. All results are normalized to non-metal
treated control cells and the housekeeping gene HSP90ABI. Results are the average of 6 and 5 biological
replicates, for BE(2)C and SH-SY5Y cells, respectively. Each biological replicate is the average of
3 technical replicates. Standard errors are presented in parentheses.
Cell Line No Treatment Pb Zn Co Li
BE(2)C 1 1.66 (0.77) 24.58 (6.23) 1.45 (0.46) 1.16 (0.37)
SH-SY5Y 1 0.97 (0.04) 16.19 (2.13) 1.18 (0.14) 1.35 (0.27)
Table 4. Relative MT3 mRNA levels after metal treatment. All results are normalized to non-metal
treated control cells and the housekeeping gene HSP90ABI. Results are the average of 6 and 5 biological
replicates, for BE(2)C and SH-SY5Y cells, respectively. Each biological replicate is the average of 3
technical replicates. Standard errors are presented in parentheses.
Cell Line No Treatment Pb Zn Co Li
BE(2)C 1 1.30 (0.34) 1.20 (0.44) 1.99 (0.58) 1.16 (0.16)
SH-SY5Y 1 0.66 (0.14) 0.76 (0.28) 1.17 (0.28) 1.23 (0.33)
3. Discussion
Metallothioneins are small proteins whose molecular simplicity belies a history replete with
efforts to definitively determine their function [20–22]. As a member of this protein family known
for its confusing biochemical functions, MT3 plays an even more opaque role in mammalian biology.
The presented work strives to provide an insight into the biology of MT3 by studying the factors that
regulate its expression as well as characterizing the degree of structural changes conferred by the
binding of the protein with different metal ions.
Metallothioneins are thought to act as zinc chaperones transporting zinc ions to their target
locations and perhaps facilitating their release when warranted [1]. Consistent with this function,
most metallothioneins are upregulated by high levels of zinc. The presence of a metal response
element (MRE) in the promoter region of MT1 and MT2 causes most metallothioneins to be induced by
zinc [3]. The MRE is activated via interaction with the zinc finger-containing metal transcription factor
1 (MTF1) [23]. MTF1 is responsible for regulating a number of genes associated with heavy metals and
oxidative stress [23]. Metallothionein is the prototypical gene target for MTF1.
Metallothioneins are also thought to function as “heavy metal sponges,” binding toxic metal
ions and potentially sequestering them. Heavy metals, including cadmium and silver, have been
repeatedly shown to increase metallothionein levels. However, the effect is an indirect one. Heavy
metals affect MT levels because they displace zinc from metallothionein, and the displaced zinc binds
to the metal transcription factor, which in turn binds to the MRE and activates the transcription of
metallothioneins [24]. Interestingly, despite the fact that lead is a heavy metal, it has never been clear
whether lead affects the levels of any metallothioneins [25–27]. We recently showed that lead can
displace zinc from Mt3 with an equilibrium constant of about 1 × 104 and thus should be able to
displace zinc in vivo, leading to the upregulation of MTs by the mechanism described above [12].
Nevertheless, some published studies show no change in MT levels following lead treatment [17],
while others do show a change [28].
Metallothioneins have also long been associated with a role in ameliorating oxidative stress [22].
MTs can release Zn2+ and two electrons while forming a disulfide bond. This may be relevant to
immune responses and inflammation [22,29]. MTF1 also binds to the metal response element of other
genes involved in cellular redox homeostasis, including selenoproteins H and W [30,31]. Thus, it is
speculated that metallothioneins and other proteins involved in combatting oxidative stress will be
simultaneously overexpressed under conditions of oxidative stress.
Very significantly, however, MT3 appears to be regulated differently from other mammalian
metallothioneins [18,32]. MT3 does not appear to respond to zinc levels in either astrocytes or neurons
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in the same way that other MTs respond to zinc, even though the promoter region of MT3 has several
regions that are similar to the metal response elements that regulate MT1 and MT2 levels [1,5,17,19,32].
MTF1 does not bind to the MRE sequence in the MT3 promoter region [32].
Both our cell culture data and our microarray data are consistent with the assertion that, in the
brain, MT3 is regulated differently from other metallothioneins. Our cell culture data shows that, in
two different neuronal cell lines, addition of zinc leads to a significant overexpression of MT2, while
having essentially no effect on MT3.
The microarray data demonstrate that, among a group of littermate-matched mice, approximately
half the population (Group A) had statistically significant upregulation of Mt2 and S100b, while the
other half of the population (Group B) had statistically significant upregulation of Mt3 and a number
of known zinc transporters (S100a6, Slc30a1, Slc39a7, Slc30a3, Slc39a3, and Ap3d1), as well as Nrx2 and
Atp13a2. The fact that Mt2 was highly expressed in Group A while Mt3 was highly expressed in Group
B indicates that these two genes are regulated differently. Furthermore, the observation that Mt3 was
upregulated along with a number of other zinc transporters suggests that this protein has a role in zinc
homeostasis in the brain.
Of particular note is the differential pattern of coexpression of members of the S100 family. S100b,
which was upregulated together with Mt2, expresses a calcium- and zinc-binding protein involved in
immune responses. S100a6, which is upregulated with Mt3, expressed a calcium- and zinc-binding
protein that has been associated with misregulation of zinc levels in several neurodegenerative
diseases [33]. S100a6 is overexpressed in mouse models of amyotrophic lateral sclerosis (ALS) and
Alzheimer’s disease and is speculated to contribute to disease progression via its high affinity for
zinc [34]. It has also been associated with cell proliferation and neuronal degeneration, processes
with which MT3 is also associated [35–38]. Other researchers have noted that S100b and S100A6 are
differentially expressed in human cortical tissue and have speculated that despite being members of
the same family of enzymes they play different neurochemical roles [38]. S100b has been linked to
neuronal growth, including the formation of neurite extension [38], while S100a6 has been associated
with cytoskeletal dynamics (as has MT3 [7,8]) [39]. S100a6 is known to be upregulated under conditions
of oxidative stress [39]. S100b has been associated with the protective effects of nutritional zinc against
methyl mercury exposure [40], as well as linked to MT2 expression in bipolar mood disorder [41].
Additional studies are underway in our laboratories to further explore the molecular mechanisms that
link this differential expression of MT2/S100b and MT3/S100A6.
There are a few factors that have been reported to affect MT3 expression. These include lithium
(downregulation), age (upregulation) and hypoxia (upregulation), but in each case, the molecular
mechanism for this regulation is not understood. Lithium was shown to decrease MT3 expression
in mice that were given lithium chloride [15]. Our cell culture results, however, showed essentially
no effect of lithium on MT3 levels. The antidepressant eugenol has also been shown to induce Mt3
expression in the hippocampus of mice while having no effect on Mt1 levels [42]. Both of these
experiments further suggest that MT3 may play a role in aspects of brain chemistry not normally
associated with metallothionein function and also point to regulation of MT3 by a non-MRE pathway.
MT3 levels increase with age [36,43–46]. In mice brains, Mt3 was found in higher concentrations
after 12 weeks of age [43]. In rat brains, a very large increase in Mt3 levels was seen when the rats
passed middle age (16 months) [36]. The authors speculate that, because MT3 has more Cu-thionein
character, its upregulation could indicate an enhanced role in copper chelation to protect the aging
brain from copper redox toxicity. However, it is unclear by what mechanism aging could lead to higher
MT3 levels [36].
MT3 also responds to hypoxia [45–47]. In one study of hypoxia, MT3 was the gene most
sensitive to hypoxia, with 3- and 7-fold increases in expression levels after 10 and 30 min treatments,
respectively [45]. In another study, MT3 levels increased by a factor of more than 600 in 60 min
upon exposure to hypoxic conditions [46]. MT3 gene expression can also reportedly be substantially
induced by hypoxia mimetics (CoCl2, desferrioxamine, dimethyloxalylglycine), which indicates that
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it is transcriptionally regulated through HIF1 [46]. Hypoxia has been suggestively linked to an
imbalance in zinc homeostasis [47]. Also, while other metallothioneins have been shown to respond
to hypoxia, in the case of other MTs, activation via the MRE was implicated [48]. Again, in our cell
culture experiments, the hypoxia mimic Co2+ showed essentially no effect on either MT2 or MT3
expression levels.
It is challenging to study factors that influence MT3 levels, and our work illustrates this as well.
Few established cell lines express MT3 to levels comparable to the levels that have been measured in
the brain [31]. In this study, we selected two different neuronal cell lines, both of which were known to
have measurable but not extremely high MT3 levels, making it possible to study treatments that might
lead to increased (or decreased) gene and protein expression. Even still, the cell culture work does not
appear to capture all of the complexity visible in animal models.
Considering that MT3 is in so many respects similar to MT1 and MT2, how can one explain its
strikingly different neurochemistry? Part of the answer presumably rests with the small structural
differences between MT3 and other MTs [49]. The unique N-terminal sequence of MT3 is required
for the growth inhibitory activity of MT3 in the neural system [50]. It has also been shown to be
responsible for Cd2+-induced death of the proximal tubule cell [50]. These amino acids have also
been shown to be responsible for zinc-specific MT3 binding to actin [7]. Protein–protein interactions,
modulated by MT3’s unique structure, may be critical to many of MT3’s neurochemical functions [9,49].
The 3D structure of metallothionein is determined by metal binding. Thioneins are unstructured and
unfolded in the absence of metal ions and then fold into bilobal proteins upon binding seven divalent
metal ions [51,52]. Suprametalation has been suggested to cause the protein to rearrange to form a
single, more globular structure [53]. Apo-MT2 and apo-MT3 in solution have practically identical
structures with low helical content [54], supporting the common notion that apo-metallothioneins
exhibit little or no secondary structure [55]. In the presence of metals, however, metallothioneins fold
into varied structures. Metallothioneins bind divalent metals such as Zn2+ and Cd2+ in tetrahedrally
coordinated M3S9 and M4S11 binding clusters, separated with sections of random coil. These structures
are characterized by circular dichroism spectra that show a positive peak at 240 nm [56].
We and others have speculated that some of the neurotoxic effects of lead exposure might
be mediated by differences in metallothionein structure when bound to lead vs. zinc [12,57,58].
Zinc prefers a coordination number of four, corroborated by its tetrahedral coordination with thiol
sites [56]. In contrast to the coordination chemistry of Zn2+, that of Pb2+ is much more complex
and varied [59,60]. Recent evidence indicates few four-coordinate Pb(II) complexes; they are either
three-coordinate or five-coordinate [31]. Possibly, lead’s (potentially) stereochemically active lone
pair plays a role in determining its geometric preferences [30,32]. He et al. speculate that lead forms
a trigonal pyramidal coordination when bound to MT2 with three sulfurs and electron donating
oxygens (Pb–S3O) [57]. The known differences in metal binding preferences between MT3 and other
metallothioneins, including the presence of an 8th metal binding site in MT2, is likely to effect the
overall structure of metal-replete MT3 [54,61,62]. Work is ongoing to determine if these structural
differences lead to functional differences in the way that MT3 interacts with partner proteins [9].
Part of the answer also presumably lies with the differential expression of MT3. This work
confirms the differential expression of MT3 but does not elucidate what the molecular mechanism is
by which it is regulated. Additional work in our labs is also underway to test hypotheses associated
with regulatory pathways for MT3.
4. Materials and Methods
4.1. Materials
Metal salts used in this work include: lead acetate (99–103%, Thermo Fisher Scientific, Waltham,
MA, USA), zinc sulfate monohydrate (99%, Strem Chemicals, Newburyport, MA, USA), cobalt
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(II) chloride hexahydrate (98.0–102.0%, Sigma Aldrich, St. Louis, MO, USA), and lithium sulfate
monohydrate (99%, Sigma Aldrich).
An ÄKTA Pure 25 L FPLC (GE Healthcare, Pittsburgh, PA, USA) was used for protein purification,
and a Forma Anaerobic System 1025 (Thermo Forma, Marietta, OH, USA) was used for anaerobic
protein manipulations. Low-speed centrifugation was done with an Allegra X-30R benchtop centrifuge
(Beckman Coulter, Indianapolis, IN, USA) and higher speed centrifugation above 10,000 rpm was
done with an Avanti J-265 XPI superspeed centrifuge (Beckman Coulter). Sonication was done with
a Vibra-Cell VC 505 Ultrasonic Liquid Processor (Sonics & Materials, Inc., Newtown, CT, USA), and
lyophilization was done on a FreeZone 2.5 Liter Benchtop Freeze Dry System (Labconco, Kansas City,
MO, USA). UV-Vis spectra were taken on a Varian Cary 50 UV-Vis spectrometer (Agilent Technologies,
Santa Clara, CA USA).
MES, MOPS, and bis-Tris buffers were purchased in highest purity from Sigma Aldrich
(St. Louis, MO, USA), as were metal salts, dithiothreitol (DTT), and 5,5′-dithiobis-(2-nitrobenzoi
acid) (DTNB). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) was purchased from Thermo
Fisher Scientific (Waltham, MA, USA). Thrombin from bovine plasma was obtained from GE Healthcare
Life Sciences (Pittsburgh, PA, USA). GSTrap FF columns, HiTrap desalting columns, and a HiLoad
26/600 75 pg size exclusion column were also purchased from GE Healthcare Life Sciences (Pittsburgh,
PA, USA). All buffers were prepared with milli-Q (18.2 MΩ·cm) water, filtered through 0.22 µm
filter unit, and degassed under vacuum until no air bubbles were seen. Metal stock solutions were
prepared using the appropriate mass of metal salt and then diluted with oxygen-free buffers in the
anaerobic chamber.
4.2. Animal Studies Ethics Statement and Animal Use
All animal care and testing protocols were approved by the Institutional Animal Care and Use
Committee at Columbia University, animal welfare assurance # A3007-01 (31 July 2013).
C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and bred to
establish colonies at the Columbia University animal facility (New York City, NY, USA). All mice were
group-housed according to institutional guidelines, with water and a commercial mouse diet available
ad libitum. Gene expression analysis was performed on age- and sex-matched mice (8- to 12-week-old;
61 females, 63 males).
4.3. Tissue Preparation
The dentate gyrus (DG) was dissected from adult mice hippocampi under a stereomicroscope
using an established method [63]. Brains were collected from deeply anesthetized mice and placed
into ice-cold phosphate-buffered saline (PBS). After exposing the medial side of the brain, the DG was
isolated and retrieved using forceps. DG tissue was placed directly into cryovials containing RNAlater
and kept at 4 ◦C overnight. The following day, RNAlater was removed, and samples were frozen at
−80 ◦C until further use.
4.4. RNA Extraction, Amplification, and Gene Expression Microarray Experiments
Before tissue homogenization, all surfaces and instruments were wiped clean with an Ambion
RNaseZap RNase decontamination solution (Thermo Fisher Scientific). RNA was extracted from DG
tissue according to RNeasy Mini Kit instructions (Qiagen, Germantown, MD, USA). DG tissues of
individual mice were homogenized using a Powergen 700 homogenizer (Thermo Fisher Scientific) in
the kit lysis buffer. Samples were quantified spectrophotometrically using a NanoDrop 2000 (Thermo
Fisher Scientific) and further analyzed using a 2100 Bioanalyzer (Agilent Technologies).
10 ng of the extracted RNA were amplified using an Ambion MessageAmp II aRNA Amplification
Kit in vitro transcription protocol following the manufacturer instructions (Thermo Fisher Scientific).
The resulting aRNA was purified using an Ambion MEGAclear Transcription Clean-Up Kit (Thermo
Fisher Scientific), and 2.5 µg of aRNA from each sample were labeled with AlexaFluor647 or
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AlexaFluor536 using RNA alkylation with monoreactive cisplatin dye complexes from an Invitrogen
ULYSIS Nucleic Acid Labeling Kits (Molecular Probes, Thermo Fisher Scientific). To correct for
dye-related sensitivity bias in the downstream detection of hybridization signals, the dye selection
was balanced between the sample groups across the experiment. Using spectroscopic measurements
of the labeled probes, labeling efficiencies were estimated as 0.5–1.5% of the dye with respect to RNA
bases. The labeled aRNA samples were hybridized to SurePrint G3 Mouse GE 8x60K Microarray Kit
(Agilent) following the manufacturer instructions. After hybridization, the microarray slides were
scanned on the two channels using Agilent C scanner (Agilent), and the image segmentation, gridding,
and feature extraction were performed using the onboard Scan Control software (v.8.5.1).
4.5. Analysis of Microarray Data
The raw hybridization signal intensities were normalized within the arrays by Agilent software
following global normalization using the loess function from the Bioconductor package affy
(v.1.42.3) [64,65]. Background filtering was performed on Agilent’s “Well Above Background” flag
function using score modulation between the relevant groups of the samples. For a gene to be scored
as present, the gene expression signals must be flagged “Well Above Background” in more than 50%
of samples within a group. Gene function assignments were done using Gene Ontology (AmiGO,
v.2.4.26) [66]. The resulting data were imported into the Spotfire (v.7.6.1) for Functional Genomics
Suite (TIBCO, New York City, NY, USA) for data visualization and further review using PCA and
hierarchical clustering. Analysis of differential gene expression was performed using a t-test followed
by Benjamini-Hochberg multiple testing correction [67]. Differentially expressed genes for functional
enrichment surveys were selected at FDR < 0.05 and fold change of 1.3. Functional enrichment analysis
in differentially expressed genes was carried out with DAVID (v.6.8) [68].
4.6. General Cell Culture and Metal Treatment
Human neuroblastoma cell lines, BE(2)C and SH-SY5Y (ATCC), were cultured in 1X Dulbecco’s
Modified Eagle Media (DMEM) with 4.5 g/L glucose and L-glutamine without sodium pyruvate
(Corning Inc., Corning, NY, USA), supplemented with 10% fetal bovine serum (FBS, Thermo Fisher
Scientific) using standard mammalian cell culture procedures. Cells were maintained at 37 ◦C and 5%
CO2 in a humidified incubator.
One day prior to metal treatment, BE(2)C and SH-SY5Y cells were seeded at 400,000 BE(2)C cells
or 450,000 SH-SY5Y cells per well onto tissue culture treated 6-well plates (2 mL media per well).
At designated treatment times, the cell culture media was replaced with 2 mL of fresh DMEM with
10% FBS and 100 mM metal solutions of lead acetate, zinc sulfate, cobalt chloride, or lithium sulfate
were added to the media to a final concentration of 100 µM metal ion.
4.7. Total RNA Extraction, cDNA Synthesis, and qPCR
Prior to RNA extraction, metal containing media was aspirated from the cells and the cells
were washed with PBS. Total RNA was extracted using the PureLinkTM RNA Mini Kit (Invitrogen)
according to manufacturer’s instructions for monolayer cells. The quantity and relative purity of the
total RNA was measured by UV-Vis spectroscopy on a Nanodrop 2000 spectrophotometer using the
absorbance at 260 nm and the 260/280 nm ratio, respectively. All RNA were stored at −80 ◦C until
further use.
Total cellular messenger RNA were reverse transcribed using the First Strand cDNA Synthesis
(Quick Protocol, New England BioLabs, Ipswich, MA, USA). Within each trial, total RNA used for
reverse transcription were maximized and standardized within the range of 200–1000 ng of RNA.
To amplify only the mRNA transcripts, an anchored poly-DT primer (5 mg/mL, IDT DNA) was used.
Complementary DNA (cDNA) synthesis was performed in a thermocycler (Bio-Rad, Hercules, CA,
USA) according to the following protocol: 42 ◦C for 60 min, 80 ◦C for 10 min. The extracted cDNA was
incubated at 4 ◦C for immediate use and stored at −20 ◦C for future use.
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Real time quantitative PCR (qPCR) was performed using PowerUP SYBR Green Master Mix
(Thermo Fisher Scientific) according to the manufacturer’s protocol for a 20 µL reaction using 2 µL
of the cDNA product as the PCR template. MT3, MT2, and the housekeeping gene HSP90AB1 were
quantified (in triplicate) for each metal treatment condition as well as the non-treatment control. The
primers used for quantitative PCR amplification of MT2, MT3, and HSP90AB1 cDNA are listed in
Table 5. A LightCycler 480 instrument (Roche Molecular Diagnostics, Pleasanton, CA, USA) was used
for qPCR amplification and monitoring, according to the PowerUp SYBR Green Master Mix thermal
cycling protocol guidelines. Based on the primers used, the annealing temperature for the qPCR was
set at 58 ◦C. qPCR data was analyzed using the ∆∆CP method [69]. The presence of MT3 in the cell
lines was confirmed by western blot analysis and by SDS-PAGE gels with purified Mt3 as a control.
Table 5. Reverse transcription and PCR primers used in this study.
Primer Sequence Tm (◦C)
Anchored Poly DT 5′ TTT TTT TTT TTT TTT TTT TTV N 3′ 41.0
HSP90 Primer 1 5′ TCC TTC TCT CGT TCC TTC TCC 3′ 55.7
HSP90 Primer 2 5′ GTA CCA AAG TGA TCC TCC ATC T 3′ 54.0
MT-2 Forward 5′ CCG ACT CTA GCC GCC TCT T 3′ 59.0
MT-2 Reverse 5′ GTG GAA GTC GCG TTC TTT ACA 3′ 55.3
MT-3 Forward 5′ CTG CGG AGT GTG AGA AGT GT 3′ 57.1
MT-3 Reverse 5′ TTG TCA TTC CTC CAA GGT CA 3′ 53.6
4.8. Protein Purification
Recombinant mouse Zn7-Mt3 was purified by following a modified protocol from our
previous study [12,70,71]. Cells were induced at OD600 ~0.7 by adding 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). After incubation at room temperature and 250 rpm for 1 h, ZnCl2
was added to a final concentration of 0.5 mM, and the cultures were incubated at 37 ◦C and 250 rpm
for 16–18 h.
Cells were thawed, separated into approximately 15 g portions, and each portion was suspended
in a solution of 1.248 g sucrose in 15 mL PBS (140 mM NaCl, 2.7 mM KCl 10 mM Na2HPO4, 1.8 mM
KH2PO4). Argon was bubbled through the mixture before centrifuging at 8000× g for 30 min at 4 ◦C
and collecting the pellets. To a suspension of the pellet in 15 mL PBS, 5.7 mM β-mercaptoethanol
(BME) was added. After bubbling with argon, the suspension was centrifuged at 8000× g for 30 min
at 4 ◦C. The pellets were collected and resuspended in PBS to a total volume of 15 mL. Just before
sonicating the solution for 7 min, with 10 s rest every 5 s, 1 mM DTT and 0.1 mM phenylmetylsulfonyl
fluoride (PMSF) were added. The lysed cells were then centrifuged at 8000× g for 30 min at 4 ◦C. The
supernatant was collected and centrifuged at 35,000 rpm for 30 min to remove any particulate matter.
A Bradford standard assay using bovine serum albumin (BSA) was used to determine the protein
concentration of the cell lysate.
Using previously published protocols, GST-tagged Mt3 protein was separated via GSTrap FF
columns and cleaved using bovine plasma thrombin [12]. Mt3 was isolated via HiLoad 26/600 75 pg
size exclusion column. Mt3 concentration was determined by measuring the absorbance of the samples
in 1 mM HCl at 220 nm and calculating using an extinction coefficient of 53,000 M−1·cm−1 [62]. The
presence of Mt3 was confirmed by SDS-PAGE on a 15% polyacrylamide gel, either with silver or
Coomassie staining and florescence imaging on bromobimane-modified MT3 samples [72].
Mt3 was concentrated and buffer-exchanged into Milli Q water using 3 kDa Amicon centrifugal
filter units. The concentrate was lyophilized overnight, and reconstituted in Tris-HClO4 buffer to
maintain the pH at 7.0. Mt3 concentration was determined both by using a DTNB assay measuring the
concentration of free thiols (20 free thiols per protein) and by measuring the absorbance at 220 nm in
1 mM HCl as described above.
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MT2 Human metallothionein-2 protein
MT2 Human metallothionein-2 gene
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